PhysioGenix’s Substantial Growth in 2010 Expected to Continue in 2011

PhysioGenix experienced a tremendous year through the completion of a new research facility, addition of capabilities and record high sales. Milwaukee, WI (PRWEB) March 23, 2011 -- PhysioGenix, already a leader in customer focused contract research, expanded their research facilities, capabilities and research models in 2010. “We experienced tremendous growth in 2010 and anticipate additional growth in 2011,” stated PhysioGenix’s Director of Sales Darin Evans. PhysioGenix was a...

U.S. Scientists Contribute to Japan Earthquake and Pacific Tsunami Relief Effort

PhysioGenix, a diabetes and cardiovascular Preclinical Contract Research Organization, donates money to the American Red Cross to aid in the Japan earthquake and Pacific tsunami relief effort. Milwaukee, WI (PRWEB) March 20, 2011 -- PhysioGenix has donated to the American Red Cross to help provide relief for the recent earthquake and tsunami victims. PhysioGenix has been in e-mail contact with several of their Japanese colleagues who have informed them that they and their families are all...

Wisconsin Announces Top Companies to Watch

Yesterday, Wisconsin's Department of Commerce announced their top 30 companies to watch in 2010.  The purpose of the award is to honor second-stage companies that demonstrate high performance in the marketplace, exhibit innovative products, services or processes, or otherwise make their company "worth watching."  Among these companies were numerous pharmaceutical and biotechnology companies whose focus are chronic diseases. The list included the following: EraGen...

Envoy Enters Diabetes and Obesity Collaboration with Merck & Co., Inc.

Envoy Therapeutics, Inc. today announced that it has entered into a multi-year research collaboration agreement with an affiliate of Merck & Co., Inc. to discover novel diabetes and obesity drug targets. Under the agreement, Envoy will use its proprietary bacTRAP® technology to identify proteins expressed specifically in certain cell types. Merck will then work to identify and develop compounds that modulate protein targets with therapeutic potential for the treatment of metabolic...

For Dekker, It’s Always Flu Season

When Cornelia Dekker, MD, was an intern in 1976, a surprise outbreak of swine flu at Fort Dix, N.J, set health care providers scrambling to immunize Americans against a possible epidemic. Instead of causing widespread disease, the virus disappeared as unexpectedly as it had come, piquing Dekker’s interest in the mysteries of influenza. After three decades of studying viral infections, Dekker, now professor of pediatrics in infectious disease at Stanford, again finds herself trying to...